Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026GlobeNewsWire · Sep 28, 2026
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026
Attovia Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 3, 2026
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewsWire · Sep 2, 2026
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More247 Wallst · Aug 31, 2026
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source24/7 Wall Street · Aug 17, 2026A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.